Creating affordable vaccines to prevent Salmonella Paratyphi A infections
Official title: Development of Robust and Low-cost Vaccines Against Salmonella Paratyphi A
Funded at Glaxosmithkline Biologicals · NIH-10929956 · Data updated 2026-11-12
This study is testing new, affordable vaccines to help protect young children from Salmonella Paratyphi A, which can cause serious foodborne illnesses, with the hope of making these vaccines available in areas where the disease is common.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Glaxosmithkline Biologicals NIH-funded |
| Lab location | 1 site (Rixensart, Belgium) |
| Project start | September 15, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $809,070 |
| NIH project number | 5R01AI177143-02 |
| Project ID | NIH-10929956 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children under 5 years old, particularly in regions where Salmonella infections are common.
✕Less likely to help
Patients who are older than 5 years or those who do not reside in areas affected by Salmonella Paratyphi A may not benefit from this research.
What this research studies
This research focuses on developing low-cost vaccines to protect against Salmonella Paratyphi A, a bacterium that causes severe foodborne illnesses, particularly in young children. The project involves preclinical studies to assess the safety and immune response of two different vaccine formulations. Researchers will use animal models to evaluate how well these vaccines work and how they can be manufactured effectively. The goal is to create a vaccine that can be widely distributed, especially in regions where paratyphoid fever is prevalent.
Why it matters
Potential benefit: If successful, this research could significantly reduce the incidence of paratyphoid fever and related deaths in young children.
How similar studies have gone: Previous research has shown promise in developing vaccines for similar bacterial infections, indicating a potential for success with this approach.
Where this research is happening
-
Glaxosmithkline Biologicals
Rixensart, Belgium Active
Researchers
- Principal investigator: Canals Alvarez, Rocio — Glaxosmithkline Biologicals
- Study coordinator: Canals Alvarez, Rocio
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.